JP2024503924A5 - - Google Patents

Info

Publication number
JP2024503924A5
JP2024503924A5 JP2023545254A JP2023545254A JP2024503924A5 JP 2024503924 A5 JP2024503924 A5 JP 2024503924A5 JP 2023545254 A JP2023545254 A JP 2023545254A JP 2023545254 A JP2023545254 A JP 2023545254A JP 2024503924 A5 JP2024503924 A5 JP 2024503924A5
Authority
JP
Japan
Prior art keywords
immunoconjugate
seq
radioactive metal
antigen
binding domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023545254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503924A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/050673 external-priority patent/WO2022162549A2/en
Publication of JP2024503924A publication Critical patent/JP2024503924A/ja
Publication of JP2024503924A5 publication Critical patent/JP2024503924A5/ja
Pending legal-status Critical Current

Links

JP2023545254A 2021-01-27 2022-01-26 カリクレイン関連ペプチダーゼ2抗原結合ドメインを含む免疫コンジュゲート及びその使用 Pending JP2024503924A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163142147P 2021-01-27 2021-01-27
US63/142,147 2021-01-27
US202163144586P 2021-02-02 2021-02-02
US63/144,586 2021-02-02
PCT/IB2022/050673 WO2022162549A2 (en) 2021-01-27 2022-01-26 Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses

Publications (2)

Publication Number Publication Date
JP2024503924A JP2024503924A (ja) 2024-01-29
JP2024503924A5 true JP2024503924A5 (enExample) 2025-01-30

Family

ID=80447388

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545254A Pending JP2024503924A (ja) 2021-01-27 2022-01-26 カリクレイン関連ペプチダーゼ2抗原結合ドメインを含む免疫コンジュゲート及びその使用

Country Status (9)

Country Link
US (1) US20250325718A1 (enExample)
EP (1) EP4284446A2 (enExample)
JP (1) JP2024503924A (enExample)
KR (1) KR20230142482A (enExample)
AU (1) AU2022213825A1 (enExample)
CA (1) CA3205707A1 (enExample)
IL (1) IL304656A (enExample)
MX (1) MX2023008803A (enExample)
WO (1) WO2022162549A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
SG11201811482YA (en) 2016-06-23 2019-01-30 Univ Cornell Double targeted constructs to affect tumor kill
KR102724812B1 (ko) 2017-04-05 2024-11-01 코넬 유니버시티 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
ES3075769T3 (en) 2019-05-10 2026-08-07 Janssen Biotech Inc Macrocyclic chelators and methods of use thereof
CR20220025A (es) 2019-07-26 2022-05-04 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos
WO2023084396A1 (en) * 2021-11-09 2023-05-19 Janssen Biotech, Inc. Macrocyclic compounds and methods of making the same
WO2023144723A1 (en) * 2022-01-26 2023-08-03 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003075855A2 (en) * 2002-03-08 2003-09-18 Protein Design Labs, Inc. Antibodies against cancer antigen tmeff2 and uses thereof
AU2006262231B2 (en) * 2005-06-20 2013-01-24 Psma Development Company, Llc PSMA antibody-drug conjugates
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
PL3248462T3 (pl) 2010-03-31 2024-07-08 Ablexis, Llc Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
WO2014093908A2 (en) 2012-12-14 2014-06-19 Omt, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
WO2015075445A1 (en) * 2013-11-19 2015-05-28 Fredax Ab Humanised anti kallikrein-2 antibody
US20180326102A1 (en) 2015-11-18 2018-11-15 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
ES2992988T3 (en) 2017-03-30 2024-12-20 Univ Cornell Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
ES3075769T3 (en) 2019-05-10 2026-08-07 Janssen Biotech Inc Macrocyclic chelators and methods of use thereof
CR20220025A (es) * 2019-07-26 2022-05-04 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos
CN114727632A (zh) 2019-09-27 2022-07-08 J-制油株式会社 加工肉制品的制造方法

Similar Documents

Publication Publication Date Title
CN101287498B (zh) Psma抗体-药物缀合物
KR20070100346A (ko) 크립토 결합 분자
KR20140085544A (ko) 항체 및 면역접합체 및 이들의 용도
WO2022162549A2 (en) Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
US6670456B2 (en) Actinium-225 complexes and conjugates for targeted radiotherapy
Song et al. An efficient bifunctional decadentate ligand 3p-C-DEPA for targeted alpha radioimmunotherapy applications
KR20240014479A (ko) 전립선암의 치료를 위한 조성물 및 방법
Schubert et al. Novel tumor pretargeting system based on complementary l-configured oligonucleotides
AU2002306598A1 (en) Actinium-225 complexes and conjugates for targeted radiotherapy
CA3070610A1 (en) Methods and compositions for targeting disease related cell surface receptors using radiolabeled and/or cytotoxin labelled antibodies
US8119103B2 (en) Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates
Zimmermann et al. A triglycine linker improves tumor uptake and biodistributions of 67-Cu-labeled anti-neuroblastoma MAb chCE7 F (ab′) 2 fragments
WO2025183075A1 (ja) 抗cdh3ヒト化抗体及びそれらの使用
JP5099919B2 (ja) 二官能性金属キレートコンジュゲート
Imam Status of radioimmunotherapy in the new millennium
US20150071853A1 (en) Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and use thereof
Brechbiel et al. Anti-HER2 radioimmunotherapy
US20250339570A1 (en) Radioimmunoconjugates and therapeutic uses thereof
CN101316615A (zh) 双官能金属螯合共轭物
JP2026515739A (ja) Steap2標的化化合物及びその使用
ES2541907T3 (es) Secuencias de nucleótidos y proteínas de un anticuerpo dirigido frente a un epítopo común para ferritínas humanas ácidas y básicas, anticuerpos monoclonales o moléculas semejantes a anticuerpo que comprenden estas secuencias y uso de éstos.
EP4469095A1 (en) Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
HK40105645A (en) Compositions and methods for the treatment of prostate cancer
HK40098620A (en) Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
CN117396234A (zh) 用于治疗前列腺癌的组合物和方法